Coadministration of posaconazole and sirolimus in allogeneic hematopoietic stem cell transplant recipients

Bone Marrow Transplant. 2016 Jul;51(7):1022-4. doi: 10.1038/bmt.2016.112. Epub 2016 Apr 25.

Authors

R Greco¹, M C Barbanti¹, M T Lupo Stranghellini¹, F Giglio¹, M Morelli¹, C Messina¹, A Forcina¹, C Oltolini², S Piemontese¹, P Scarpellini², S Marktel¹, A Assanelli¹, M Carrabba¹, L Vago^{1

3}, C Corti¹, M Bernardi¹, J Peccatori¹, F Ciceri^{1

4}

Affiliations

¹ Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milano, Italy.
² Infectious Disease Unit, IRCCS San Raffaele Scientific Institute, Milano, Italy.
³ Unit of Immunogenetics, Leukemia Genomics and Immunobiology, IRCCS San Raffaele Scientific Institute, Milano, Italy.
⁴ University Vita-Salute, Milano, Italy.

PMID: 27111047
DOI: 10.1038/bmt.2016.112

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Adult
Aged
Female
Follow-Up Studies
Hematopoietic Stem Cell Transplantation*
Hodgkin Disease / therapy
Humans
Leukemia, Myeloid, Acute / therapy
Lymphoma, Non-Hodgkin / therapy
Male
Middle Aged
Multiple Myeloma / therapy
Remission Induction
Risk
Sirolimus / administration & dosage*
Transplantation Conditioning*
Transplantation, Homologous
Treatment Outcome
Triazoles / administration & dosage*
Young Adult

Substances

Triazoles
posaconazole
Sirolimus